Section 4.9: Clinical Pharmacology: Endocrine & Metabolic Disorders

Clinical Pharmacology: Endocrine & Metabolic Disorders

Endocrine and metabolic disorders encompass high-yield therapeutic areas including diabetes mellitus (types 1 and 2), thyroid dysfunction, osteoporosis, and adrenal disorders. Dosing calculations, contraindications, and class-specific adverse effects are heavily tested on the SPLE.

---

1. Diabetes Mellitus (T1DM and T2DM)

Diagnosis Criteria

• Fasting Plasma Glucose (FPG): >= 126 mg/dL (after >= 8 hours of fasting)
• 2-Hour Post-Prandial Glucose: >= 200 mg/dL during an Oral Glucose Tolerance Test (OGTT)
• Hemoglobin A1c (HbA1c): >= 6.5%
• Random Plasma Glucose: >= 200 mg/dL in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis

Type 1 Diabetes (T1DM)

T1DM is characterized by autoimmune destruction of beta-cells, leading to absolute insulin deficiency. Treatment requires physiological basal-bolus insulin regimens:

• Basal Insulin (Long-acting): e.g., Glargine, Detemir, Degludec. Administered once or twice daily to suppress glucose production between meals and overnight.
• Prandial/Bolus Insulin (Rapid-acting): e.g., Aspart, Lispro, Glulisine. Administered before meals to cover carbohydrate intake.
• Kinetics: Rapid-acting insulins onset in 5–15 minutes, peak in 1–2 hours, and last 3–5 hours. Short-acting (Regular) insulin onsets in 30 minutes, peaks in 2–3 hours, and lasts 5–8 hours.

Type 2 Diabetes (T2DM) Pharmacotherapy

For T2DM, therapy selection is patient-centered. While Metformin remains the foundational first-line therapy (unless contraindicated), choice of add-on therapy is driven by the presence of compelling comorbidities:

Comorbidities:
- Heart Failure (HF) or Chronic Kidney Disease (CKD):
  * SGLT2 Inhibitor (Empagliflozin, Dapagliflozin) - preferred because they reduce HF hospitalizations and slow CKD progression.
- Established Atherosclerotic Cardiovascular Disease (ASCVD) or High Risk:
  * GLP-1 Receptor Agonist (Liraglutide, Semaglutide) OR SGLT2 Inhibitor with proven CV benefit.

Oral and Injectable Hypoglycemic Agent Profiles

---

2. Thyroid Disorders

Hypothyroidism

Characterized by low free T4 and elevated TSH. The treatment of choice is Levothyroxine (synthetic T4):

• Standard Replacement Dose: 1.6 mcg/kg/day (IBW) in young, healthy adults.
• Elderly or Ischemic Heart Disease starting dose: 12.5 to 25 mcg daily to prevent precipitating angina, myocardial infarction, or arrhythmias due to rapid cardiotonic effects.
• Monitoring: Check TSH levels every 6–8 weeks until euthyroid, then annually.
• Patient Counseling: Take with water on an empty stomach, at least 30–60 minutes before breakfast (or at bedtime, 3–4 hours after the last meal). Space at least 4 hours apart from calcium, iron, antacids, and bile acid sequestrants.

Hyperthyroidism

Characterized by high free T4 and suppressed TSH. Treatment options include thionamides:

• Methimazole: Preferred agent for most patients due to a lower risk of hepatotoxicity and once-daily dosing.
• Propylthiouracil (PTU): Preferred in the first trimester of pregnancy (Methimazole is associated with embryopathy, e.g., aplasia cutis) and in the treatment of propthyroid storm (due to its additional mechanism of inhibiting the peripheral conversion of T4 to T3).
• Warnings: Both agents can cause agranulocytosis (counsel patients to report fever, sore throat, or signs of infection immediately) and hepatotoxicity (PTU has a black box warning for severe liver injury).

---

3. Osteoporosis

Osteoporosis is diagnosed by a bone mineral density (BMD) T-score of <= -2.5 (by DXA scan) or the presence of a fragility fracture.

Pharmacotherapy Classes

• Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic acid): First-line therapy. Inhibit osteoclast-mediated bone resorption.
  • Oral Administration: Must be taken first thing in the morning with a full glass of plain water (no coffee, juice, or tea) on an empty stomach. The patient must remain upright for at least 30 minutes (60 minutes for ibandronate) to prevent severe esophageal irritation and ulceration.
  • Adverse Effects: Esophagitis, atypical femur fractures, and osteonecrosis of the jaw (ONJ). Contraindicated if eGFR < 35 mL/min (or < 30 mL/min for ibandronate).
• Denosumab: Monoclonal antibody targeting RANKL, preventing osteoclast maturation. Administered subcutaneously every 6 months. Critical warning: must not be delayed or stopped abruptly due to a rapid rebound in bone resorption and vertebral fracture risk.
• Teriparatide & Abaloparatide: Recombinant human parathyroid hormone analogs (anabolic agents). Stimulate osteoblasts. Restricted to 2 years lifetime use due to a black box warning for osteosarcoma (seen in animal studies).
• Romosozumab: Sclerostin inhibitor (dual anabolic and antiresorptive). Black box warning: increased risk of myocardial infarction, stroke, and cardiovascular death; avoid in patients with a history of MI or stroke within the preceding year.

---

4. Adrenal Insufficiency

Adrenal insufficiency involves deficient production of glucocorticoids and/or mineralocorticoids.

• Primary (Addison's Disease): Loss of both cortisol and aldosterone production. Requires glucocorticoid replacement (e.g., Hydrocortisone 15–25 mg daily in divided doses, or Prednisone) AND mineralocorticoid replacement (Fludrocortisone 0.05–0.2 mg daily).
• Secondary Adrenal Insufficiency: Pituitary failure leading to deficient ACTH. Only glucocorticoid replacement is needed (aldosterone is regulated by the RAAS, not ACTH).
• Stress Dosing: Patients must be counseled to double or triple their oral glucocorticoid dose during periods of illness, fever, or minor trauma ("sick day rules"). Injectable hydrocortisone must be available for severe stress or vomiting.